FI103987B1 - Interleukin-7 - Google Patents

Interleukin-7

Info

Publication number
FI103987B1
FI103987B1 FI902077A FI902077A FI103987B1 FI 103987 B1 FI103987 B1 FI 103987B1 FI 902077 A FI902077 A FI 902077A FI 902077 A FI902077 A FI 902077A FI 103987 B1 FI103987 B1 FI 103987B1
Authority
FI
Finland
Prior art keywords
mammalian
interleukin
dnas
proteins
products
Prior art date
Application number
FI902077A
Other languages
English (en)
Finnish (fi)
Other versions
FI103987B (sv
FI902077A0 (fi
Inventor
Anthony E Namen
Raymond G Goodwin
Stephen D Lupton
Diane Y Mochizuki
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of FI902077A0 publication Critical patent/FI902077A0/fi
Application granted granted Critical
Publication of FI103987B publication Critical patent/FI103987B/sv
Publication of FI103987B1 publication Critical patent/FI103987B1/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI902077A 1987-10-26 1990-04-25 Interleukin-7 FI103987B1 (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11356687A 1987-10-26 1987-10-26
US11356687 1987-10-26
US8803747 1988-10-19
PCT/US1988/003747 WO1989003884A1 (en) 1987-10-26 1988-10-19 Interleukin-7

Publications (3)

Publication Number Publication Date
FI902077A0 FI902077A0 (fi) 1990-04-25
FI103987B FI103987B (sv) 1999-10-29
FI103987B1 true FI103987B1 (sv) 1999-10-29

Family

ID=22350177

Family Applications (1)

Application Number Title Priority Date Filing Date
FI902077A FI103987B1 (sv) 1987-10-26 1990-04-25 Interleukin-7

Country Status (14)

Country Link
EP (1) EP0314415B1 (sv)
JP (1) JP2749838B2 (sv)
AT (1) ATE109829T1 (sv)
AU (1) AU616456B2 (sv)
CA (1) CA1340491C (sv)
DE (1) DE3851035T2 (sv)
DK (1) DK175865B1 (sv)
FI (1) FI103987B1 (sv)
IE (1) IE64159B1 (sv)
IL (1) IL88151A (sv)
NO (1) NO302824B1 (sv)
NZ (1) NZ226679A (sv)
WO (1) WO1989003884A1 (sv)
ZA (1) ZA887773B (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041313B1 (en) 1980-04-03 1990-09-12 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
ZA943348B (en) 1993-05-21 1995-11-16 Hirano Toshio A gene encoding a polypeptide having pre-B cell growth-supporting ability
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
RO115788B1 (ro) * 1994-03-31 2000-06-30 Amgen Inc. Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
EP2314696A1 (en) * 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2362381C (en) 1999-02-10 2009-12-22 Welfide Corporation Amide compounds and medicinal use thereof
DE10137792A1 (de) * 2001-08-06 2003-02-27 Erdmann Volker Verfahren zur Genexpression
EP1391513A1 (en) * 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
BRPI0720001A2 (pt) 2006-12-14 2013-12-24 Schering Plough Ltd Proteína linfopoietin estromal tímica canina e usos da mesma
BR112014002365A2 (pt) 2011-08-03 2017-02-21 Cytheris interleucina-7 (il-7)
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
US10208099B2 (en) 2015-06-11 2019-02-19 Genexine, Inc. Modified interleukin-7 protein
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
TWI774651B (zh) 2015-12-04 2022-08-21 南韓商吉耐森股份有限公司 包含融合有免疫球蛋白Ｆｃ之介白素-７的用於預防或治療人類乳頭狀瘤病毒相關疾病的藥學組成物
CN108697764A (zh) 2015-12-04 2018-10-23 格纳西尼有限公司 含有免疫球蛋白fc融合白细胞介素-7融合蛋白的用于预防或治疗流感病毒感染的药物组合物
JP2022514702A (ja) 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4720482A (en) * 1982-10-20 1988-01-19 Dana Farber Cancer Institute Pharmaceutical compositions containing one or more lymphocyte growth factors
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4730036A (en) * 1984-01-03 1988-03-08 Sloan-Kettering Institute For Cancer Research Purifications of B-cell inducing factor (BIF) and B-cell growth factor (BGF)
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
JPS6490199A (en) * 1987-09-30 1989-04-06 Hiromi Fujiwara T cell growth factor derived from thymic interstitial cell and production thereof

Also Published As

Publication number Publication date
IL88151A (en) 1993-01-31
JPH05268971A (ja) 1993-10-19
DK175865B1 (da) 2005-04-18
NO302824B1 (no) 1998-04-27
JP2749838B2 (ja) 1998-05-13
DK302089A (da) 1989-06-19
NO892630L (no) 1989-06-23
DE3851035D1 (de) 1994-09-15
IE883221L (en) 1989-04-26
NO892630D0 (no) 1989-06-23
IE64159B1 (en) 1995-07-12
FI103987B (sv) 1999-10-29
IL88151A0 (en) 1989-06-30
EP0314415A3 (en) 1990-05-30
NZ226679A (en) 1991-06-25
EP0314415A2 (en) 1989-05-03
FI902077A0 (fi) 1990-04-25
AU616456B2 (en) 1991-10-31
ATE109829T1 (de) 1994-08-15
DK302089D0 (da) 1989-06-19
EP0314415B1 (en) 1994-08-10
DE3851035T2 (de) 1994-12-01
CA1340491C (en) 1999-04-13
AU2827289A (en) 1989-05-23
ZA887773B (en) 1989-07-26
WO1989003884A1 (en) 1989-05-05

Similar Documents

Publication Publication Date Title
DE3851035D1 (de) Interleukin-7.
IL88472A0 (en) Mammalian interleukin-1 receptor protein dnas and expression vectors encoding them,processes for producing them and pharmaceutical compositions containing them
ES2103706T3 (es) Receptores de interleuquina-4.
ATE131871T1 (de) Rezeptoren für tumornekrosisfaktor-alpha und - beta
NO872988D0 (no) Pattedyr-interleukin-4.
ATE118036T1 (de) Interleukin-7-rezeptoren.
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
DE3850774D1 (de) Rinder-interleukin-1-alpha.
ES2061719T3 (es) Proceso para la produccion de proteinas.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: SANOFI

FG Patent granted

Owner name: SANOFI-SYNTHELABO

MA Patent expired